Catalyst Wire Dossier Catalyst Wire Dossier

ABI-110

AAV2.N54-VEGF Trap · Avirmax Biopharma Inc
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ABI-110, covering 2026-02-12 to 2026-02-12. Get the full timeline:

Most recent: Clinical Trial Update: Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) [Phase 1, Phase 2]

See pricing